Skip to content
SPACListing
CompletedNasdaq

Cardio Diagnostics Holdings, Inc.CDIO

Class A CDIOWarrants CDIOWCIK 0001870144

Cash in trust

$65.6M

$65,573,383

Trust per share

$10.08

Redemption value

IPO

Nov 2021

$65.0M raised

Combination deadline

—

Not disclosed

Filings on record

295

Latest Oct 2, 2026

Business combination

Target
Not disclosed in an indexed filing
Announced
May 31, 2022
Closed
Oct 31, 2022

Overview

Cardio Diagnostics Holdings, Inc. is a special purpose acquisition company incorporated in Delaware and registered with the SEC under CIK 0001870144. It completed its initial public offering in Nov 2021, raising $65.0M in gross proceeds and listing on Nasdaq. Class A shares trade under the ticker CDIO, warrants under CDIOW on Nasdaq. The vehicle is sponsored by Mana through Mana Capital LLC. The mandate targets technology, healthcare, consumer. Business combination closed; the company trades under a new ticker.

“we intend to focus our search on target businesses operating in North America, Europe and Asia in the healthcare, technology, green economy, and consumer products sectors.”
The mandate, as stated in the IPO prospectus
TechnologyHealthcareConsumerNorth AmericaEuropeAsia-Pacific

Reading the filings

Arithmetic on what Cardio Diagnostics Holdings, Inc. has disclosed, written the way a desk would read it. These are observations, not a rating. Nothing here scores the vehicle or implies a view on it.

  • Trust versus the $10 unit

    The trust holds $10.08 per public share, 0.8% above the $10.00 the units were sold at. That spread is accrued interest on the trust and, where the charter provides for it, sponsor contributions paid in to buy more time. It is the floor a public shareholder can redeem at, not a valuation of the business.

  • Warrant coverage

    Each unit carried one-half warrant per unit. Warrants are dilution deferred: they cost the holder nothing until exercised, and they overhang the post-combination share count. Thinner coverage is generally a sign of a stronger book at pricing.

  • Underwriting

    Ladenburg Thalmann led the offering. It has been named on 46 SPAC IPOs, book-running 11 of them, and 65% of its resolved vehicles closed a deal. The syndicate has no control over whether a sponsor finds a target, but the quality of the book at pricing shapes who ends up holding the units.

How busy it has been

Filings per month since the first one. A vehicle that has gone quiet with a deadline ahead is a different proposition from one that is still working.

17902021-072026-10

295 filings in all. 10 in the last three months, against a busiest month of 17.

News on Cardio Diagnostics Holdings, Inc.

Last 90 days

News sentiment

Neutral
negativeneutralpositive

Across 1 recent story, weighted towards the newest. Scored by our own headline classifier using finance- and SPAC-specific terms. It reads what a story is about, not what the shares are worth.

SEC filing history

Free tier: filings older than 24 hours
  • 4

    Statement of changes in beneficial ownership

    Accession 0002055040-26-000004

    Oct 2, 2026

    28d ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0002060369-26-000004

    Oct 2, 2026

    28d ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001950394-26-000004

    Oct 2, 2026

    28d ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0002006956-26-000004

    Oct 2, 2026

    28d ago

    View on EDGAR ↗
  • 8-K

    Submission of matters to a vote of security holders

    Items 5.07, 9.01 · Accession 0001553350-26-000131

    Sep 18, 2026

    1mo ago

    View on EDGAR ↗
  • DEFA14A

    Additional proxy soliciting material

    Accession 0001079973-26-001223

    Sep 8, 2026

    1mo ago

    View on EDGAR ↗
  • 8-K

    Regulation FD disclosure

    Items 7.01, 9.01 · Accession 0001079973-26-001153

    Aug 20, 2026

    2mo ago

    View on EDGAR ↗
  • 10-Q

    Quarterly report

    Accession 0001079973-26-001016

    Aug 7, 2026

    2mo ago

    View on EDGAR ↗
  • DEFA14A

    Additional proxy soliciting material

    Accession 0001079973-26-001010

    Aug 7, 2026

    2mo ago

    View on EDGAR ↗
  • DEF 14A

    Definitive proxy statement

    Accession 0001079973-26-001003

    Aug 5, 2026

    2mo ago

    View on EDGAR ↗
  • ARS

    ANNUAL REPORT TO SECURITY HOLDERS

    Accession 0001079973-26-000965

    Jul 23, 2026

    3mo ago

    View on EDGAR ↗
  • PRE 14A

    PRELIMINARY 14A

    Accession 0001079973-26-000945

    Jul 13, 2026

    3mo ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0002060369-26-000003

    Jul 2, 2026

    4mo ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0002055040-26-000003

    Jul 2, 2026

    4mo ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001950394-26-000003

    Jul 2, 2026

    4mo ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0002006956-26-000003

    Jul 2, 2026

    4mo ago

    View on EDGAR ↗
  • 10-Q

    Quarterly report

    Accession 0001553350-26-000089

    May 15, 2026

    5mo ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0002060369-26-000002

    Apr 2, 2026

    7mo ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0002055040-26-000002

    Apr 2, 2026

    7mo ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001950394-26-000002

    Apr 2, 2026

    7mo ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0002006956-26-000002

    Apr 2, 2026

    7mo ago

    View on EDGAR ↗
  • 10-K

    Annual report

    Accession 0001553350-26-000023

    Mar 13, 2026

    7mo ago

    View on EDGAR ↗
  • 8-K

    Regulation FD disclosure

    Items 7.01, 9.01 · Accession 0001079973-26-000239

    Feb 19, 2026

    8mo ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0002060369-26-000001

    Jan 6, 2026

    9mo ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0002055040-26-000001

    Jan 6, 2026

    9mo ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001950394-26-000001

    Jan 6, 2026

    9mo ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0002006956-26-000001

    Jan 6, 2026

    9mo ago

    View on EDGAR ↗
  • 10-Q

    Quarterly report

    Accession 0001079973-25-001686

    Nov 12, 2025

    11mo ago

    View on EDGAR ↗
  • 8-K

    Submission of matters to a vote of security holders

    Items 5.07, 9.01 · Accession 0001079973-25-001612

    Oct 15, 2025

    1y ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0002060369-25-000002

    Oct 3, 2025

    1y ago

    View on EDGAR ↗

Pro

Track CDIO without the delay

Free accounts see this filing history a day late. Pro shows every document minutes after EDGAR publishes it, opens it on EDGAR in one click, and adds the twelve-month deadline calendar.

  • Filings live, no 24-hour delay
  • One click through to the source document
  • Deadline calendar out to 12 months
  • CSV export, API and MCP access

Cancel any time. Billed monthly in USD.

Cardio Diagnostics Holdings, Inc.: questions answered

What is Cardio Diagnostics Holdings, Inc. (CDIO)?

Cardio Diagnostics Holdings, Inc. is a special purpose acquisition company incorporated in Delaware and registered with the SEC under CIK 0001870144. It completed its initial public offering in Nov 2021, raising $65.0M in gross proceeds and listing on Nasdaq. Class A shares trade under the ticker CDIO, warrants under CDIOW on Nasdaq. The vehicle is sponsored by Mana through Mana Capital LLC. The mandate targets technology, healthcare, consumer. Business combination closed; the company trades under a new ticker.

How much does Cardio Diagnostics Holdings, Inc. hold in trust?

Approximately $65,573,383, or about $10.08 per public share, as at the most recent filing on record. Trust balances move: shareholders redeem at extension votes and at the combination vote, and sponsors pay contributions in to extend. Treat the figure as a point-in-time disclosure, not a running balance.

When must Cardio Diagnostics Holdings, Inc. complete a merger?

No combination deadline appears in the filings we have indexed. The date is stated in the charter and repeated in each quarterly report; where our parser could not establish it with confidence we leave it blank rather than infer one.

What happens if Cardio Diagnostics Holdings, Inc. does not find a target in time?

The charter requires the vehicle to redeem 100% of the public shares and return the trust, pro rata, to public shareholders. That is the mechanism working as designed rather than a default. Founder shares and warrants are worthless in that outcome, which is why the sponsor's incentive is to get a deal done or to buy more time. Across the market, deadline lapsed without a deal; trust returned to public shareholders.

Can I redeem shares in Cardio Diagnostics Holdings, Inc., and at what price?

Public shareholders may elect to redeem in connection with a combination vote and at each extension vote, at the pro-rata trust value on the relevant record date, most recently disclosed at about $10.08 per share. Redemption is a right attached to the public shares only; warrants and rights carry no claim on the trust. The mechanics and the deadline for electing are set out in the proxy statement for the vote in question.

What tickers does Cardio Diagnostics Holdings, Inc. trade under?

Class A shares trade as CDIO on Nasdaq, and the warrants as CDIOW. Units trade first and separate into their component securities roughly 52 days after the IPO; only the Class A shares carry the redemption right against the trust.

Is the trust value the same as the share price for Cardio Diagnostics Holdings, Inc.?

No, and the gap between them is the whole trade. Trust per share is a disclosed, contractual figure of $10.08, being what a redeeming holder receives. The market price is whatever the shares change hands at: most recently $1.67, a spread to the redemption value. Quotes on this site are delayed and indicative; confirm on your own venue before trading.

How much dilution do Cardio Diagnostics Holdings, Inc.'s founder shares and warrants create?

Each unit also carried one-half warrant per unit, which is dilution deferred until exercise. Both are disclosed in the prospectus and both survive into the combined company, which is why a de-SPAC at $10 is not economically the same as an IPO at $10.

Who sponsors Cardio Diagnostics Holdings, Inc., and what is their track record?

Mana Capital LLC is the sponsor entity, part of the Mana franchise. This is the only vehicle we have attributed to that sponsor. Named principals: Jonathan Intrater.

Which banks underwrote the Cardio Diagnostics Holdings, Inc. IPO?

Ladenburg Thalmann, I-Bankers Securities. Ladenburg Thalmann was credited as book-running manager on the cover. Syndicate membership and role are read from the prospectus cover and the underwriting section.

Is Cardio Diagnostics Holdings, Inc. tradeable, and where?

Yes. CDIO returned a live quote of $1.67 on Nasdaq. Quotes here are delayed and refreshed on a schedule rather than streamed, so treat the figure as indicative and confirm on your own venue. Units and warrants trade under their own symbols and are quoted separately.

Is Cardio Diagnostics Holdings, Inc. a good investment?

That is not a question this site answers. Cardio Diagnostics Holdings, Inc. is covered here as reference data: what the company filed, when it filed it, and what the numbers in those filings say. The Edge, FOMO and Potential scores on this page are derived measures with a published formula, not ratings of investment merit: they describe the setup, and every component is shown so you can take them apart. We publish no price targets and no recommendations, and nothing here should be read as advice. The figures are a starting point for your own work, and each one carries the accession number of the filing it came from.

Where does this Cardio Diagnostics Holdings, Inc. data come from?

Filings Cardio Diagnostics Holdings, Inc. submitted to the SEC under CIK 0001870144: the registration statement and final prospectus for the structure, quarterly and annual reports for the trust, current reports and proxy statements for deals, votes and extensions. Trust economics are taken from the registrant's own XBRL tags rather than parsed from prose, which is why they are exact. Every filing in the history above is listed with its accession number, which identifies the document uniquely on EDGAR; Pro accounts open it directly from the row.

Compiled by the SPACListing research desk

Last reconciled Oct 31, 2026

Every figure on this page is read from documents the registrants filed with the U.S. Securities and Exchange Commission, principally the IPO prospectus (Form 424B4), quarterly and annual reports, current reports and proxy statements, the registrant's own XBRL tags for trust economics. Nothing is sourced from press coverage, from the companies themselves, or from a third-party aggregator. Where a filing does not disclose something, the field is left blank rather than estimated.

Read the full methodology · What is in the dataset · Report a correction

SPACListing is a reference-data service, not an investment adviser. Nothing here is a recommendation to buy or sell any security.

Continue reading

The context around this vehicle: who else the sponsor has launched, which banks priced it, and where it sits in the wider market.